Table 2.
ORR and DCR to crizotinib treatment in ALK‐rearranged NSCLC patients
| ORR | p value | DCR | p | |
|---|---|---|---|---|
| Type of ALK fusion (n = 64) | 0.726 | 0.312 | ||
| EML4‐ALK | 38 (73.1%) | 48(92.3%) | ||
| Non‐EML4‐ALK | 8 (66.7%) | 10(83.3%) | ||
| EML4‐ALK variants (n = 49) | 0.135 | 0.566 | ||
| Variant 1 | 8 (61.5%) | 12(92.3%) | ||
| Variant 2 | 9 (90.0%) | 10(100%) | ||
| Variant 3a/b | 19 (79.2%) | 21(87.5%) | ||
| Other EML4‐ALK variants | 2 (40%) | 5(100%) | ||
| TP53 status (n = 64) | 0.003 | 0.023 | ||
| Mutated | 6 (40.0%) | 11(73.3%) | ||
| Wild‐type | 40 (81.6%) | 47(95.9%) | ||
| TP53 mutation type (n = 15) | 0.136 | 0.103 | ||
| Disruptive | 4 (66.7%) | 6(100%) | ||
| Nondisruptive | 2 (22.2%) | 5(55.6%) | ||
| TP53 mutation site (n = 15) | 0.166 | 0.199 | ||
| Exon 5 | 0 | 1(33.3%) | ||
| Exon 6 | 4 (57.1%) | 6(85.7%) | ||
| Exon 7 | 0 | 1(50.0%) | ||
| Exon 8 | 2 (66.7%) | 3(100%) |
DCR, disease control rate; ORR, objective response rate.